{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:39:29Z","timestamp":1783021169104,"version":"3.54.6"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004417","name":"The Global Fund to Fight AIDS Tuberculosis and Malaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108222","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:09:48Z","timestamp":1763374188000},"page":"108222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From trials to programmatic scale-up: treatment outcomes of rifampicin-resistant tuberculosis during transition to short oral regimens in Vietnam (2021\u20132022)"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1521-3872","authenticated-orcid":false,"given":"Thi Mai Phuong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Luong","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh Hoa","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thanh Thuy","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet Nhung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108222_bib0001","first-page":"70","article-title":"The fate of cases of pulmonary tuberculosis under various treatment programmes","volume":"53","author":"Grzybowski","year":"1978","journal-title":"Bull Int Union Against Tuberc"},{"key":"10.1016\/j.ijid.2025.108222_bib0002","series-title":"Global TB report","first-page":"2024","year":"2024"},{"key":"10.1016\/j.ijid.2025.108222_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5365\/wpsar.2016.7.2.002","article-title":"Prevalence of resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients in Viet Nam, 2011","volume":"7","author":"Nguyen","year":"2016","journal-title":"Western Pac Surveill Response J"},{"key":"10.1016\/j.ijid.2025.108222_bib0004","series-title":"WHO Treatment guidelines for drug-resistant tuberculosis 2016 update","year":"2016"},{"key":"10.1016\/j.ijid.2025.108222_bib0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S2213-2600(24)00186-3","article-title":"Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (Stream stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial","volume":"12","author":"Goodall","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0006","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (Stream stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2025.108222_bib0007","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: drug resistant tuberculosis treatment","year":"2022"},{"key":"10.1016\/j.ijid.2025.108222_bib0008","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0009","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-Pretomanid-Linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0010","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5588\/pha.15.0068","article-title":"Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam","volume":"6","author":"Phuong","year":"2016","journal-title":"Public Health Action"},{"key":"10.1016\/j.ijid.2025.108222_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2344821","article-title":"Effectiveness, cost, and safety of four regimens recommended by WHO for RR\/MDR-TB treatment: a cohort study in Eastern China","volume":"56","author":"Gu","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287966","article-title":"Unsuccessful treatment outcome and associated risk factors. A prospective study of DR-TB patients from a high burden country, Pakistan","volume":"18","author":"Massud","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108222_bib0014","article-title":"Factors affecting the treatment outcome of injection based shorter MDR-TB regimen at a referral centre in India","volume":"93","author":"Kiran","year":"2022","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.ijid.2025.108222_bib0015","series-title":"Framework for implementation Active tuberculosis drug-safety monitoring and management (aDSM)","year":"2015"},{"key":"10.1016\/j.ijid.2025.108222_bib0016","series-title":"Definitions and reporting framework for tuberculosis \u20132013 revision","year":"2013"},{"key":"10.1016\/j.ijid.2025.108222_bib0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2022.11.007","article-title":"Effectiveness and safety of bedaquiline-based, modified all-oral 9\u201311-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam","volume":"126","author":"Nguyen","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108222_bib0018","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijid.2022.09.012","article-title":"Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study","volume":"124","author":"Jouego","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108222_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105844","article-title":"Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements","volume":"161","author":"Piubello","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ijid.2025.108222_bib0021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1186\/s12879-024-09745-8","article-title":"Treatment outcomes of standardized injectable shorter regimen for multi-drugs resistant tuberculosis in Ethiopia: a retrospective cohort study","volume":"24","author":"Achalu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2025.108222_bib0022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4269\/ajtmh.20-1361","article-title":"Predictors of rifampicin-resistant tuberculosis mortality among HIV-coinfected patients in Rwanda","volume":"105","author":"Habimana","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijid.2025.108222_bib0023","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.ijid.2025.108222_bib0024","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225004448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:54:03Z","timestamp":1783018443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225004448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":24,"alternative-id":["S1201971225004448"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108222","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From trials to programmatic scale-up: treatment outcomes of rifampicin-resistant tuberculosis during transition to short oral regimens in Vietnam (2021\u20132022)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108222"}}